NCI-2020-00134

A Phase 1b, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation

A Phase 1b study called a Master Protocol, this reaerch is looking at how safe and effective a drug called AMG 510 is in people with advanced solid tumors that have a specific mutation called KRAS p.G12C.

KRAS:A KRAS mutation is a specific type of alteration in the KRAS gene, which is part of the RAS gene family. These mutations can lead to uncontrolled cell growth and are commonly found in various cancers, impacting treatment outcomes and guiding therapeutic strategies.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT04185883

Clinical Trial Site: Sinai

To see all available clinical trials click here.